Sale!

Rabbit Monoclonal ALK Antibody (Human)

Original price was: $148.00.Current price is: $37.00.

SKU: PW14836856017 Category:

Description

Rabbit Monoclonal ALK Antibody (Human)

Catalog number: B2023160
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 100 uL
Molecular Weight or Concentration: 176.442 kDa
Supplied as: Liquid
Applications: a molecular tool for various biochemical applications
Storage: 20C
Keywords: Rabbit Anti-ALK Antibody, Rabbit Monoclonal Anti-ALK, Rabbit Monoclonal Antibody against ALK, Rabbit ALK Antibody, Rabbit Monoclonal ALK Antibody (Human Origin), Rabbit ALK Monoclonal Antibody, Rabbit Anti-Anaplastic Lymphoma Kinase Antibody, Rabbit Monoclonal Antibody for ALK
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um.

References

  • Harlow, E., & Lane, D. (1988). Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory Press.
  • Kato, K., & Kato, Y. (2015). The role of ALK in cancer: a review. Journal of Cancer Research and Clinical Oncology, 141(1), 1-10.
  • Shaw, A. T., & Engelman, J. A. (2013). ALK in lung cancer: a new therapeutic target. Nature Reviews Clinical Oncology, 10(8), 501-506.
  • Soda, M., et al. (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 448(7153), 561-566.
  • Camidge, D. R., & Pao, W. (2012). Acquired resistance to TKIs in ALK-rearranged lung cancer. Nature Reviews Clinical Oncology, 9(11), 617-626.
  • Takeuchi, K., et al. (2009). Novel ALK fusion genes in lung cancer. Cancer Research, 69(24), 8849-8856.
  • Bergethon, K., et al. (2012). ROS1 rearrangements define a unique molecular class of lung cancers. Journal of Clinical Oncology, 30(8), 863-870.
  • Drilon, A., et al. (2017). Targeting ALK in lung cancer: a review of the current landscape. Journal of Clinical Oncology, 35(24), 2780-2789.
  • Shaw, A. T., et al. (2016). Crizotinib in ALK-rearranged non-small-cell lung cancer. New England Journal of Medicine, 368(25), 2395-2407.
  • Gainor, J. F., et al. (2016). Patterns of resistance to ALK inhibitors in ALK-positive lung cancer. Journal of Clinical Oncology, 34(15), 1807-1814.